Clinical trials: Beta-Amyloid
Amyloid-beta
Sleep Quality and Amyloid-Beta Kinetics
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.
- Trial name
- NCT03077620
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Amyloid Beta Protein
Escitalopram Effects on CSF Amyloid Beta
Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures…
- Trial name
- NCT02161458
- Testing
- Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks
- Where
- 2 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Amyloid-beta
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle.
- Trial name
- NCT02063217
- Testing
- Sodium Oxybate, Sleep deprivation
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Down Syndrome, Amyloid Beta-protein
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS.
- Trial name
- NCT00928304
- Testing
- Florbetaben (BAY94-9172)
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.